5.23
price up icon4.39%   0.22
 
loading
Precedente Chiudi:
$5.01
Aprire:
$5.09
Volume 24 ore:
698.99K
Relative Volume:
0.92
Capitalizzazione di mercato:
$549.41M
Reddito:
$58.49M
Utile/perdita netta:
$-105.04M
Rapporto P/E:
-4.024
EPS:
-1.2997
Flusso di cassa netto:
$-13.78M
1 W Prestazione:
+15.71%
1M Prestazione:
+25.42%
6M Prestazione:
-43.94%
1 anno Prestazione:
-51.97%
Intervallo 1D:
Value
$5.06
$5.41
Intervallo di 1 settimana:
Value
$4.53
$5.41
Portata 52W:
Value
$3.30
$13.77

Immatics N V Stock (IMTX) Company Profile

Name
Nome
Immatics N V
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
423
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
IMTX's Discussions on Twitter

Confronta IMTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IMTX
Immatics N V
5.23 549.41M 58.49M -105.04M -13.78M -1.2997
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Immatics N V Stock (IMTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-07 Iniziato Piper Sandler Overweight
2023-11-02 Iniziato Cantor Fitzgerald Overweight
2023-03-31 Iniziato Mizuho Buy
2023-03-24 Iniziato Bryan Garnier Buy
2020-11-20 Iniziato BofA Securities Buy
2020-09-22 Iniziato Goldman Buy
2020-07-27 Iniziato SVB Leerink Outperform
2020-07-24 Iniziato Jefferies Buy
Mostra tutto

Immatics N V Borsa (IMTX) Ultime notizie

pulisher
Apr 30, 2025

Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals

Apr 30, 2025
pulisher
Apr 30, 2025

Guggenheim Capital LLC Takes $101,000 Position in Immatics (NASDAQ:IMTX) - Defense World

Apr 30, 2025
pulisher
Apr 25, 2025

Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World

Apr 25, 2025
pulisher
Apr 24, 2025

Are Immatics N.V (IMTX) shares a good deal now? - uspostnews.com

Apr 24, 2025
pulisher
Apr 23, 2025

Immatics Announces Upcoming Oral and Poster Presentation on IMA2 - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Immatics N.V. to Present Updated Data on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Immatics Announces Upcoming Oral and Poster Presentation on - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 - Stock Titan

Apr 23, 2025
pulisher
Apr 23, 2025

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Yahoo

Apr 23, 2025
pulisher
Apr 19, 2025

Short Interest in Immatics (NASDAQ:IMTX) Declines By 20.7% - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Immatics N.V (NASDAQ: IMTX): Moving Toward A Higher Share Price - Stocksregister

Apr 18, 2025
pulisher
Apr 07, 2025

(IMTX) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 07, 2025

Immatics N.V (NASDAQ: IMTX): Can’t Stop The Stock’s Slide? - stocksregister.com

Apr 07, 2025
pulisher
Apr 04, 2025

FY2025 EPS Estimates for Immatics Decreased by Analyst - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Financial Contrast: Novonesis A/S (OTC:NVZMY) and Immatics (NASDAQ:IMTX) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Immatics (NASDAQ:IMTX) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Research Analysts Set Expectations for Immatics Q1 Earnings - The AM Reporter

Apr 01, 2025
pulisher
Mar 31, 2025

Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Immatics Reports Strong 2024 Financial Results and Progress - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 27, 2025

Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan

Mar 27, 2025
pulisher
Mar 23, 2025

Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World

Mar 23, 2025
pulisher
Mar 17, 2025

IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

(IMTX) Trading Report - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 13, 2025

Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 08, 2025

Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St

Mar 06, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025
pulisher
Feb 21, 2025

Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register

Feb 21, 2025
pulisher
Feb 19, 2025

Financial Metrics Unveiled: Immatics N.V (IMTX)’s Key Ratios in the Spotlight - The Dwinnex

Feb 19, 2025
pulisher
Feb 19, 2025

Immatics (NASDAQ:IMTX) Sets New 1-Year Low – What’s Next? - Defense World

Feb 19, 2025
pulisher
Feb 17, 2025

(IMTX) Trading Signals - Stock Traders Daily

Feb 17, 2025
pulisher
Feb 14, 2025

Immatics (NASDAQ:IMTX) Reaches New 1-Year LowHere's What Happened - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX) - MarketBeat

Feb 14, 2025
pulisher
Feb 12, 2025

New Strong Buy Stocks for February 12th - Yahoo Finance

Feb 12, 2025
pulisher
Feb 11, 2025

Immatics (NASDAQ:IMTX) Trading Down 4.7% – What’s Next? - Defense World

Feb 11, 2025
pulisher
Feb 09, 2025

Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance

Feb 09, 2025
pulisher
Feb 08, 2025

Immatics N.V (IMTX): An Important Analyst Insights - Stocks Register

Feb 08, 2025
pulisher
Feb 07, 2025

Financial Metrics Check: Immatics N.V (IMTX)’s Ratios for Trailing Twelve Months - The Dwinnex

Feb 07, 2025
pulisher
Feb 07, 2025

Immatics (NASDAQ:IMTX) Reaches New 52-Week LowTime to Sell? - MarketBeat

Feb 07, 2025
pulisher
Feb 05, 2025

Examining Immatics N.V (IMTX) more closely is necessary - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

It is Poised to be a Bull Market for Immatics N.V (IMTX) - SETE News

Feb 04, 2025
pulisher
Feb 03, 2025

Immatics N.V (IMTX) Becoming More Attractive for Investors - Knox Daily

Feb 03, 2025
pulisher
Feb 03, 2025

Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in January - MarketBeat

Feb 03, 2025
pulisher
Feb 02, 2025

Immatics (NASDAQ:IMTX) Hits New 52-Week LowShould You Sell? - MarketBeat

Feb 02, 2025

Immatics N V Azioni (IMTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Capitalizzazione:     |  Volume (24 ore):